Abstract: The invention relates to a method of producing a single-strength spectacle lens while taking into account an individual spectacle wearer's data, the single-strength spectacle lens having a rotationally symmetrical base surface and a rotationally symmetrical aspherical or atoric prescription surface, comprising the following steps: Acquisition of an individual spectacle wearer's data; selection of a spectacle lens blank with a predetermined base surface from a group of spectacle lens blanks; and calculation and optimization of the prescription surface while taking into account at least a part of the individual spectacle wearer's data in addition to an adaptation of the dioptric effect by the prescription surface to the spectacle wearer's prescription. The invention also relates to a corresponding system for producing a single-strength spectacle lens and to an individual single-strength spectacle lens.

Abstract: This invention provides novel methods of obtaining autologous monoclonal antibodies (AMABs) to self-antigens or homologs thereof. The method involves obtaining a genetically engineered host animal that does not biosynthesize at least one epitope of the antigen and utilizes the lack of self-tolerance of the host to the epitope to produce antibodies specific to the antigen. The invention also encompasses the AMABs produced by the methods. The invention further encompasses methods of isolating cells comprising the use of such AMABs that have specificity for a cell surface antigen.

Abstract: Compounds of formula I as well as pharmaceutically acceptable salts and esters thereof, wherein R1, R2, R3, A1 and A2 have the significance given in claim 1, can be used in the form of pharmaceutical preparations for the treatment or prevention of arthritis, cardiovascular diseases, diabetes, renal failure, eating disorders and obesity.

Abstract: Compounds of formula I as well as pharmaceutically acceptable salts and esters thereof, wherein R1, R2, R3, A1 and A2 have the significance given in claim 1, can be used in the form of pharmaceutical preparations for the treatment or prevention of arthritis, cardiovascular diseases, diabetes, renal failure, eating disorders and obesity.

Abstract: In a device for dosing and transporting dry urea, e.g., for implementing the SCR method in a motor vehicle, the device includes a storage vessel containing the dry urea in the form of pellets, the wall of the storage vessel having an opening to which a transport line is connected on the outer side. The device also includes a compressed air nozzle which is arranged inside the storage vessel at a distance from the opening, is oriented towards the opening, and may be supplied with compressed air, and a portioning element having an upper side oriented towards the inside of the storage vessel and a lower side opposite the wall of the storage vessel. At least one continuous channel having a larger cross section than the dimensions of the pellets connects the upper side and the lower side in order to form at least one receiving element for the pellets.

Abstract: Compounds of formula I as well as pharmaceutically acceptable salts and esters thereof, wherein R1, R2, R3, A1 and A2 have the significance given in claim 1, can be used in the form of pharmaceutical preparations for the treatment or prevention of arthritis, cardiovascular diseases, diabetes, renal failure, eating disorders and obesity.

Abstract: Compounds of formula I as well as pharmaceutically acceptable salts and esters thereof, wherein R1, R2, R3, A1 and A2 have the significance given in claim 1, can be used in the form of pharmaceutical preparations for the treatment or prevention of arthritis, cardiovascular diseases, diabetes, renal failure, eating disorders and obesity.

Abstract: The present invention relates to compounds of formula (I): wherein —X—Y—, R1 to R11 and n are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prevention of diseases which are mediated by CETP inhibitors.

Abstract: A spectacle lens is provided with a region (distance portion) designed for viewing at greater distances and, in particular, “to infinity”, a region (near portion) designed for viewing at short distances and, in particular, “reading distances”, and a progression zone disposed between the distance portion and the near portion, in which the power of the spectacle lens increases from the value in the distance reference point located in the distance portion to the value at the near reference point located in the near portion along a line (principal meridian) curving towards the nose. The invention is marked by specific conditions for the astigmatic deviation and/or the mean “as worn” power being observed.

Abstract: A method is provided for producing ammonia (NH3) and introducing the produced ammonia (NH3) into an exhaust gas stream as a reduction means for selectively catalytically reducing nitrogen oxides contained in the exhaust gas stream, which is an exhaust stream generated by the combustion process of a motor, a gas turbine, or a burner. The method comprises feeding dry urea from a supply container in a controlled amount to reactor and subjecting the dry urea in the reactor to a sufficiently rapid thermal treatment such that a gas mixture comprising the reaction products of ammonia (NH3) and isocyanic acid (HCNO) is created. Also, the method comprises immediately catalytically treating the thus produced gas mixture in the presence of water such that the isocyanic acid (HCNO) resulting from the rapid thermal treatment is converted, via quantitative hydrolysis treatment, into ammonia (NH3) and carbon dioxide (CO2).

Abstract: A device for coupling and decoupling two shafts or other elements of a drive train for transmitting rotations or torques especially to be used as a clutch segment in the field of motorcycle drives is provided. The clutch segment includes two parts one of which comprise troughs or recesses being arranged on a circle and offset by essentially the same angle. The troughs are at least approximately tangentially abutting an inner circle. The troughs linearly extend from their deepest point, beginning with a radius of the inner circle, at an angle towards an edge thereof and turn over towards the edge of a radius. A force application point for applying a force for coupling or decoupling the elements is located at a distance from a rotation axis of the clutch segment.

Abstract: Quinoline derivatives are useful as neuropeptide Y (NPY) receptor ligands and are particularly effective as neuropeptide Y (NPY) antagonists. These compounds are useful in pharmaceutical preparations for the treatment or prevention of arthritis, cardiovascular diseases, diabetes, renal failure, eating disorders, or obesity.

Abstract: The object of the present invention is to provide a method for the detection and/or quantification of the 14-3-3 proteins or their isoforms for early stage diagnosis of TSE-diseases, which method allows to perform the diagnosis in the living organism. It is furthermore an object, to detect a contamination of the sample by the parallel determination of a second antigen. This object according to the invention is solved by making use of the biochemical characteristics of the members of the 14-3-3 protein family, which bind to specific amino acid motifs like X(n)-XSXXSXXSX-X(n) or to the motif RSXpSXP (SEQ ID NO: 12) within peptides or proteins. For determining one or more isoforms or the entirety of the 14-3-3 protein(s) and for specific binding, one uses modified solid phases like e.g. microtiter plates, which are coated with a synthetic or natural peptide containing a binding motif for 14-3-3 proteins, e.g. a chemically synthesised peptide having the motif CAALPKINRSApSEPSLHR (SEQ ID NO: 1).

Abstract: Compounds of formula I 1

Abstract: The present invention relates to a modular optical sensor device having an optical base module and a supplemental or supplementary module. The supplemental module may be disposed on the optical base module and replaced by other supplemental optical modules. The supplementary optical modules have different lighting characteristics. Depending on the kind of the object to be detected, a supplemental module can be chosen which is suitable with respect to the lighting angle and the spectral distribution of the illuminating light. According to one embodiment, the optical base module is coupled to the supplemental optical module via an interface so that the supplemental optical module can be identified by a central control unit and the optical sensor device does not have to be calibrated when the supplemental module is exchanged.

Abstract: The invention relates to substituted 5-benzyl-2,4-diaminopyrimidines of general formula (A) wherein R1 is C2-C3 alkyl an R2 is heterocyclyl, phenyl or naphthyl, bonded by one of its C-atoms and R3 is C2-C6 alkyl, alkenyl, cycloalkyl, cycloalkylalkyl, heterocyclylalkyl, alkylsulfonyl, cycloalkylsulfonyl, cycloalkylalkylsulfamoyl, heterocyclysylfonyl, heterocyclylalkylsulfonyl or dialkylsulfamoyl; wherein alkyl, cycloalkyl and alyenyl can carry up to 6 carbon atoms alone or in compositions and can carry up to 6 ring members heterocyclically, alone, or in compositions and the groups R2 and R3 can be substituted; and to acid addition salts of compounds. The invention also relates to a method for producing the above 5-benzyl-2,4-diaminopyrimidines, to the intermediate. products that are produced, to corresponding medicaments and to the use of 5-benzyl-2,4-diaminopyrimidines as medicinal preparations.

Abstract: Quinoline derivatives are useful as neuropeptide Y (NPY) receptor ligands and are particularly effective as neuropeptide Y (NPY) antagonists. These compounds are useful in pharmaceutical preparations for the treatment or prevention of arthritis, cardiovascular diseases, diabetes, renal failure, eating disorders, or obesity.

Abstract: Compounds of formula I as well as pharmaceutically acceptable salts and esters thereof, wherein R1, R2, R3, A1 and A2 have the significance given in claim 1, can be used in the form of pharmaceutical preparations for the treatment or prevention of arthritis, cardiovascular diseases, diabetes, renal failure, eating disorders and obesity.

Abstract: The present invention relates to compounds of formula (I) 1

Abstract: The invention relates to a method for remote-control programming and to a machine control system 2 for performing the method. To refine the method so as to simplify and shorten an execution operation of a control program source yet automatically avoid version conflicts between the control program source and the compilate in the machine control system, it is proposed that the program source 3a stored in memory in the machine control system be executed by means of a programming device 1, and after the execution, the compilate of the executed program source is generated and stored in memory in the machine control system, where it is made available to a control module.